JNJ
STELARA’s cloud, J&J’s flex
Johnson & Johnson is basically telling Wall Street, “Sure, STELARA is getting some biosimilar competition — but that’s not the whole movie.” The company said it still expects to deliver double-digit growth, leaning on a mix of medicines, medical devices, and pipeline programs to do the heavy lifting.
Why investors care
When a blockbuster drug starts facing copycats, the first instinct is to wonder whether the whole growth story is about to wobble like a table with one short leg. J&J’s pitch here is the opposite: the company wants you to focus on the broader portfolio, not just one product.
What’s doing the work:
- medicines that can offset pressure on older giants
- medical devices, which add a steadier, less dramatic revenue stream
- pipeline programs that could keep the next wave of launches rolling
The bigger picture
This is the classic pharma balancing act: lose exclusivity on one blockbuster, then try to prove you’re not a one-hit wonder. J&J is leaning hard into the idea that scale, diversification, and a deep bench of products can smooth out the STELARA hit.
Big picture: if management can keep that double-digit-growth story alive, investors may be willing to give J&J the benefit of the doubt — even with biosimilars circling like sharks.